歡迎光臨源葉生物,登錄 | 注冊(cè) |
當(dāng)前位置: 首頁 > 小分子抑制劑 > CellCycle/Checkpoint > XMD8-92

瀏覽歷史

S81258

XMD8-92

源葉(MedMol) 99%
  • 英文名:
  • 2-[[2-ethoxy-4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one
  • 別名:
  • XMD8-92; XMD-8-92; XMD 8-92; XMD892; XMD-892; XMD 892.
  • CAS號(hào):
  • 1234480-50-2
  • 分子式:
  • C26H30N6O3
  • 分子量:
  • 474.57
  • 核磁/質(zhì)譜:
品牌貨號(hào)產(chǎn)品規(guī)格價(jià)格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購物車...
源葉(MedMol) S81258-5mg 99% ¥245.00元 10 - - - EA 加入購物車
源葉(MedMol) S81258-10mg 99% ¥395.00元 10 - - - EA 加入購物車
源葉(MedMol) S81258-50mg 99% ¥1590.00元 2 - - - EA 加入購物車
源葉(MedMol) S81258-100mg 99% ¥2550.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購物車
大包裝詢價(jià)

提交您的電話號(hào)碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 提示:詳情請(qǐng)下載說明書。
  • 產(chǎn)品描述: XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with Kds of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with Kds of 190, 600 and 890 nM, respectively. Anti-cancer activity
  • 靶點(diǎn): BMK1:80 nM (Kd);BRD4:190 nM (Kd);ERK;?BMI-1;?EpigeneticReaderDomain
  • 體外研究:
    XMD8-92 (0-5 Μm; 48 hours) inhibits the proliferation of HMEC and cancer cells.
    XMD8-92 effectively inhibits BMK1 activation as well as induces PML’s (promyelocytic leukemia protein) downstream effector, p21. XMD8-92 significantly inhibits basic fibroblast growth factor (bFGF) induced angiogenesis in Matrigel plugs. XMD8-92 significantly induces p21 expression in HeLa and A549 cells. Cell Viability Assay Cell Line: HMEC, A549 and HeLa cells Concentration: 0.16, 0.32, 0.63, 1.25, 2.5 or 5 μM Incubation Time: 48 hours Result: Inhibited the proliferation of HMEC and cancer cells.
  • 體內(nèi)研究:
    XMD8-92 (i.p.; twice a day for 28 days) significantly inhibits the growth of the xenografted human tumors. Animal Model: HeLa Xenograft Model (6-week-old Nod/Scid mice)[1] Dosage: 50 mg/kg Administration: I.p.; twice a day for 28 days Result: Significantly inhibited the growth of the xenografted human tumors.
  • 參考文獻(xiàn):
    1. Yang Q, et al. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.Cancer Cell. 2010 Sep 14;18(3):258-67. 2. Yang Q, et al. Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin Cancer Res. 2011 Jun 1;17(11):3527-32. 3. Lin EC, et al. ERK5 kinase activity is dispensable for cellular immune response and proliferation. Proc Natl Acad Sci U S A. 2016;113(42):11865-11870. 4. Umapathy G, et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014 Oct 28;7(349):ra102.
  • 溶解性: soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.107 ml 10.536 ml 21.072 ml
    5 mM 0.421 ml 2.107 ml 4.214 ml
    10 mM 0.211 ml 1.054 ml 2.107 ml
    50 mM 0.042 ml 0.211 ml 0.421 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。